Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Gene Expression Regulation, Neoplastic*; AC133 Antigen/*metabolism ; Neoplastic Stem Cells/*pathology ; Stomach Neoplasms/*genetics ; Stomach Neoplasms/*pathology ; Stromal Cells/*pathology; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Cell Line, Tumor ; Embryonic Stem Cells/pathology ; Epithelial-Mesenchymal Transition/genetics ; Gene Expression Profiling ; Humans ; Neoplastic Stem Cells/metabolism ; Prognosis ; Stomach Neoplasms/metabolism ; Stromal Cells/metabolism ; Survival Analysis
    • Abstract:
      Background: The CD133 transmembrane protein is a well-recognized stem cell marker that has been used to isolate putative cancer stem cell populations from gastric cancers (GCs). However, the molecular features or biomarkers underlying CD133 are largely unknown in GCs.
      Methods: We performed gene expression profiling of CD133+ and CD133- cells sorted by flow cytometry from three GC cell lines to identify the CD133 expression signatures of GC. The CD133 expression signatures were investigated across publicly available expression profiles of multiple tumor types including GC and also for their relationship with patient survival.
      Results: The CD133 signature genes defined as 177 upregulated genes and 129 downregulated genes in CD133+ cells compared to CD133- cells were enriched with genes involving the cell cycle and cytoskeleton, implying that cancer stem cells with unlimited self-renewal play cancer-initiating roles. The CD133 expression signatures in GC expression profiles were positively correlated with those of brain tumors expressing CD133 and human embryonic stem cells, emphasizing the transcriptional similarities across stem cell-related expression signatures. We also found that these stem cell expression signatures were inversely correlated with those representing tumor infiltrating immune and stromal cells. Additionally, high CD133 expression signatures were found in intestinal subtypes and low tumor stage GCs as well as in those with microsatellite instabilities and high mutation burdens. As examined across 20 additional tumor types, both the expression signatures representing CD133 and stromal cells were unfavorable prognostic features; however, their impact were variable across tumor types.
      Conclusions: The transcriptional activities of CD133 and those of stromal cells representing the activity of stem cells and level of epithelial-to-mesenchymal transition, respectively, may be inversely correlated with each other across multiple tumor types including GC. This relationship may be a confounding factor and should therefore be considered when evaluating the clinical relevance of stem cell-related markers.
    • References:
      Mol Cell Biol. 1999 Mar;19(3):1720-30. (PMID: 10022859)
      Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
      Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
      Curr Opin Oncol. 2007 Jan;19(1):61-4. (PMID: 17133114)
      Nat Med. 2008 May;14(5):518-27. (PMID: 18438415)
      Nat Genet. 2008 May;40(5):499-507. (PMID: 18443585)
      Lancet. 2009 Aug 8;374(9688):477-90. (PMID: 19625077)
      Nature. 2009 Nov 5;462(7269):108-12. (PMID: 19847166)
      BMC Cancer. 2010 May 20;10:218. (PMID: 20487522)
      Anticancer Res. 2010 Jun;30(6):2453-7. (PMID: 20651407)
      J Exp Clin Cancer Res. 2010 Nov 07;29:141. (PMID: 21054902)
      Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1591-6. (PMID: 21220328)
      Br J Cancer. 2011 Aug 23;105(5):658-65. (PMID: 21829201)
      Nat Rev Cancer. 2012 Jan 12;12(2):133-43. (PMID: 22237392)
      J Surg Oncol. 2012 Dec;106(8):999-1004. (PMID: 22674531)
      PLoS One. 2013;8(3):e59154. (PMID: 23533603)
      Gastric Cancer. 2014 Jan;17(1):97-106. (PMID: 23558457)
      Nat Commun. 2013;4:2612. (PMID: 24113773)
      PLoS One. 2013 Oct 04;8(10):e76773. (PMID: 24124593)
      World J Gastroenterol. 2014 May 14;20(18):5420-6. (PMID: 24833872)
      Nature. 2014 Sep 11;513(7517):202-9. (PMID: 25079317)
      Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
      Nat Med. 2015 May;21(5):449-56. (PMID: 25894828)
      N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
      Gastroenterology. 2015 Oct;149(5):1153-1162.e3. (PMID: 26073375)
      World J Gastroenterol. 2015 Oct 7;21(37):10510-27. (PMID: 26457012)
      Oncotarget. 2015 Dec 8;6(39):42019-27. (PMID: 26503471)
      Nat Commun. 2015 Dec 04;6:8971. (PMID: 26634437)
      Medicine (Baltimore). 2016 Oct;95(42):e5163. (PMID: 27759647)
      Cancer Immunol Res. 2018 Jan;6(1):87-97. (PMID: 29141981)
      Electrophoresis. 1997 Mar-Apr;18(3-4):533-7. (PMID: 9150937)
    • Grant Information:
      2015R1A1A1A05028000 National Research Foundation of Korea; HI15C1578 Republic of Korea Korea Health Industry Development Institute; HI15C3224 Republic of Korea Korea Health Industry Development Institute; 2018R1D1A1B07045486 National Research Foundation of Korea
    • Contributed Indexing:
      Keywords: CD133; Cancer stem cells; Expression signature; Gastric cancers; Survival
    • Accession Number:
      0 (AC133 Antigen)
      0 (Biomarkers, Tumor)
      0 (PROM1 protein, human)
    • Publication Date:
      Date Created: 20190206 Date Completed: 20190830 Latest Revision: 20200225
    • Publication Date:
      20231215
    • Accession Number:
      PMC6360664
    • Accession Number:
      10.1186/s12885-019-5332-y
    • Accession Number:
      30717708